CAS NO. |
Products Name |
956697-53-3 |
NVP-LDE225 |
more... |
LDE225 (NVP-LDE225; Erismodegib) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. |
|
1408064-71-0 |
JNK-IN-7 |
more... |
JNK-IN-7 is a relatively selective JNKs inhibitor(IC50= 1.54/1.99/0.75 for JNK1/2/3); also bound to IRAK1, PIK3C3, PIP5K3 and PIP4K2C. |
|
733030-01-8 |
TAS-102 |
more... |
TAS-102 is a novel oral combination drug that consists of an antineoplastic thymidine-based nucleoside analog, trifluorothymidine, and a potent thymidine phosphorylase inhibitor, tipiracil, in a 1:0.5 molar ratio. |
|
|
1234563-16-6 |
Epetraborole hydrochloride |
more... |
Epetraborole hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor, which inhibits protein synthesis by binding "to the terminal adenosine ribose (A76) of leucyl-tRNA synthetase". It is intended for the treatment of infections caused by Gram-negative bacteria. |
|
1640282-31-0 |
I-CBP112 |
more... |
I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that targets the CBP/p300 bromodomains. |
|
1883429-22-8 |
BI-9564 |
more... |
BI-9564 is a selective, and cell-permeable BRD9 BD inhibitor, with Kd of 5.9 nM for BRD9, and IC50 of > 100 μM for BET family. |
|
1313363-54-0 |
NVP-CGM097 |
more... |
NVP-CGM097(CGM-097) is a potent and selective MDM2 inhibitor; an orally bioavailable HDM2 antagonist with potential antineoplastic activity. |
|
1224887-10-8 |
GSK2256098 |
more... |
GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells. |
|
|
|
1420071-30-2 |
Bioymifi |
more... |
Bioymifi(DR5 Activator) is the first novel and potent small-molecule activatior of the TRAIL receptor DR5 in human cancer cells. |
|